Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

A "Hansard" written answer referred to those "inadvertently" infected with Hepatitis C through infected blood transfusions.

  • Read more about A "Hansard" written answer referred to those "inadvertently" infected with Hepatitis C through infected blood transfusions.

A "Dear Doctor" letter from Dr Kenneth Calman referred to those "inadvertently" infected with Hepatitis C through infected blood transfusions.

  • Read more about A "Dear Doctor" letter from Dr Kenneth Calman referred to those "inadvertently" infected with Hepatitis C through infected blood transfusions.

In a letter to Lord Fraser QC, Tom Sackville at the Department of Health referred to those "inadvertently" infected with Hepatitis C through infected blood transfusions.

  • Read more about In a letter to Lord Fraser QC, Tom Sackville at the Department of Health referred to those "inadvertently" infected with Hepatitis C through infected blood transfusions.

The Archer Report found that "The United Kingdom delayed testing until a specific test (as opposed to a surrogate test) became available. Even then, although such a test was in use in Japan in 1989, and in the USA, Australia and most European countries in 1990, the United Kingdom delayed introduction until the product had been approved by the Food and Drug Administration (FDA) in the USA, and it was not introduced into the United Kingdom until September 1991."

  • Read more about The Archer Report found that "The United Kingdom delayed testing until a specific test (as opposed to a surrogate test) became available. Even then, although such a test was in use in Japan in 1989, and in the USA, Australia and most European countries in 1990, the United Kingdom delayed introduction until the product had been approved by the Food and Drug Administration (FDA) in the USA, and it was not introduced into the United Kingdom until September 1991."

In his statement to the Inquiry, Alan Johnson acknowledged that the High Court's 2001 finding that the UK should have introduced screening or surrogate testing earlier should have been reflected in the briefing dated 27 May 2009.

  • Read more about In his statement to the Inquiry, Alan Johnson acknowledged that the High Court's 2001 finding that the UK should have introduced screening or surrogate testing earlier should have been reflected in the briefing dated 27 May 2009.

A briefing from the Secretary of State's Office for the Parliamentary Labour Party asserted that "Action was taken as soon as possible to introduce testing and safety measures for blood and blood products as these became available."

  • Read more about A briefing from the Secretary of State's Office for the Parliamentary Labour Party asserted that "Action was taken as soon as possible to introduce testing and safety measures for blood and blood products as these became available."

A briefing provided for Alan Johnson, the Secretary of State for Health, and Dawn Primarolo asserted that "as soon as technologies (heat treatment and testing) were available to improve safety, they were introduced."

  • Read more about A briefing provided for Alan Johnson, the Secretary of State for Health, and Dawn Primarolo asserted that "as soon as technologies (heat treatment and testing) were available to improve safety, they were introduced."

In a letter to the Manor House Group, Dawn Primarolo, Minister of State for Public Health, repeated the line that donor screening for Hepatitis C could not have been implemented sooner and that "the Government of the day acted in good faith, relying on the technology available at the time."

  • Read more about In a letter to the Manor House Group, Dawn Primarolo, Minister of State for Public Health, repeated the line that donor screening for Hepatitis C could not have been implemented sooner and that "the Government of the day acted in good faith, relying on the technology available at the time."

William Connon wrote to Dawn Primarolo, the Minister of State for Public Health, and to Lord Hunt in response to media reports of an announcement of a public inquiry. The lines to take included "the Government of the day acted in good faith, relying on the technology available at the time" and donor screening for Hepatitis C could not have been implemented sooner.

  • Read more about William Connon wrote to Dawn Primarolo, the Minister of State for Public Health, and to Lord Hunt in response to media reports of an announcement of a public inquiry. The lines to take included "the Government of the day acted in good faith, relying on the technology available at the time" and donor screening for Hepatitis C could not have been implemented sooner.

Caroline Flint approved the draft follow up letter from the Department of Health's Customer Service Centre to campaigner Sue Threakall containing a longer explanation, which included the line that "viral inactivation processes, heat treatment and screening tests were developed and introduced as soon as practicable."

  • Read more about Caroline Flint approved the draft follow up letter from the Department of Health's Customer Service Centre to campaigner Sue Threakall containing a longer explanation, which included the line that "viral inactivation processes, heat treatment and screening tests were developed and introduced as soon as practicable."

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 431
  • Page 432
  • Page 433
  • Page 434
  • Current page 435
  • Page 436
  • Page 437
  • Page 438
  • Page 439
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.